HSD17B7: A Potential Drug Target for Various Diseases (G51478)

Target Name: HSD17B7

NCBI ID: G51478

HSD17B7

HSD17B7: A Potential Drug Target for Various Diseases

HSD17B7, also known as 17beta-hydroxysteroid dehydrogenase type 7, is a gene that encodes a protein in the cytosol of mammalian cells. The protein produced by this gene is involved in the metabolism of 17beta-hydroxysteroids, which are naturally occurring compounds found in the body. HSD17B7 is an enzyme that converts 17beta-hydroxysteroids to 17beta-hydroxylated steroids, which are then excreted from the body.

The HSD17B7 gene has been identified as a potential drug target in the treatment of various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. The reason for its potential as a drug target is its involvement in the regulation of important signaling pathways in the body , as well as its role in the development and progression of various diseases.

One of the key functions of HSD17B7 is its role in the regulation of cell signaling pathways. The cytosol of mammalian cells contains a variety of signaling molecules that are involved in the regulation of cell growth, differentiation, and survival. HSD17B7 is involved in the breakdown of these signaling molecules, converting them into less potent forms that are then excreted from the body. This function of HSD17B7 is critical for maintaining the integrity and balance of signaling pathways in the cytosol, and for preventing the development of diseases associated with the imbalance of these signaling pathways.

Another function of HSD17B7 is its role in the regulation of inflammation. The cytosol of mammalian cells contains a variety of signaling molecules that are involved in the regulation of inflammation and immune responses. HSD17B7 is involved in the breakdown of these signaling molecules, converting them into less potent forms that are then excreted from the body. This function of HSD17B7 is critical for maintaining the integrity and balance of signaling pathways related to inflammation, and for preventing the development of diseases associated with the imbalance of these signaling pathways.

In addition to its role in the regulation of cell signaling pathways and inflammation, HSD17B7 is also involved in the regulation of other important physiological processes in the body. For example, HSD17B7 is involved in the regulation of bone growth and development, and is thought to play a role in the development and progression of diseases associated with osteoarthritis, such as osteoarthritis. HSD17B7 is also involved in the regulation of hair growth and is thought to play a role in the development and progression of diseases associated with hair loss, such as androgen-dependent alopecia.

The potential drug targets for HSD17B7 are vast and varied. In addition to its role in the regulation of cell signaling pathways and inflammation, HSD17B7 is also involved in the regulation of other important physiological processes in the body, including bone growth and development, and hair growth. This makes HSD17B7 an attractive target for the development of drugs for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

The development of drugs that target HSD17B7 is still in its infancy, and much research is needed to fully understand its role in the regulation of cell signaling pathways and other important physiological processes in the body. However, the potential targets for HSD17B7 make it an exciting area of 鈥嬧?媟esearch, and one that has the potential to lead to the development of new treatments for a variety of diseases.

Protein Name: Hydroxysteroid 17-beta Dehydrogenase 7

Functions: Bifunctional enzyme involved in steroid-hormone metabolism and cholesterol biosynthesis (PubMed:12574203, PubMed:12732193, PubMed:12829805, PubMed:20659585, PubMed:19772289, PubMed:11165030). Catalyzes the NADP(H)-dependent reduction of estrogens and androgens and regulates the biological potency of these steroids. Converts estrone (E1) to a more potent estrogen, 17beta-estradiol (E2) (PubMed:12574203, PubMed:12732193, PubMed:19772289). Converts dihydrotestosterone (DHT) to its inactive form 5a-androstane-3b,17b-diol (PubMed:12574203, PubMed:12732193, PubMed:19772289). Converts moderately progesterone to 3beta-hydroxypregn-4-ene-20-one, leading to its inactivation (PubMed:12574203, PubMed:12732193). Additionally, participates in the post-squalene cholesterol biosynthesis, as a 3-ketosteroid reductase (PubMed:12829805, PubMed:20659585, PubMed:11165030)

The "HSD17B7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets